Lead sponsor
Zhejiang Doer Biologics Co., Ltd.
5 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 6, 2026.
5
Trials led
3
Ongoing
1,200
Total enrollment
41
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
1
Phase 2
2
Phase 3
2
Trials by status
Not yet recruiting
2
Active, not recruiting
1
Completed
2
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe HypertriglyceridemiaBMI 19-45Ph 3Not yet recruiting480
A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe HypertriglyceridemiaBMI 19-45Ph 3Not yet recruiting378
A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624BMI 18-32Ph 1Completed153
Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD SubjectsBMI 25-40Ph 2Active, not recruiting110